Amoy Diagnostics SZSE:300685 Stock Report

Amoy Diagnostics Co., Ltd. Competitors

About the Company

Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on development and commercialization of diagnostics product for oncology in China and internationally. It offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions for evaluating PARP inhibitor-related biomarkers and advancing targeted treatment research in ovarian cancer; AmoyDx HRD complete panel to detect genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel that covers various protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes; AmoyDx handle classic NGS panel to detect multiple gene mutations in cancer patients for treatment; and AmoyDx essential NGS panel to detect EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET genes in patients with non-small cell lung cancer and colorectal cancer using FFPE or liquid biopsy samples. The company also provides AmoyDx handle HRR NGS panel for detection of somatic and germline variants; AmoyDx pan lung cancer PCR panel, a tissue-based real-time qPCR assay for in vitro diagnostics; AmoyDx myeloid blood cancer panel; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx PD-L1 (E1L3N) assay; and AmoyDx handle melanoma NGS panel to detect single nucleotide variants, insertions, and deletions within pivotal melanoma tumor genes.